AstraZeneca (AZN) – PRNewswire
-
SOPHiA GENETICS and AstraZeneca Spain Commit to Increasing Ovarian Cancer Testing in Spain
-
Compugen to Receive $10 Million Milestone Payment Following Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer
-
Allorion Therapeutics Announces Exclusive Option and Global License Agreement for Novel Preclinical-Stage EGFR L858R Allosteric Inhibitor Program with AstraZeneca
-
Compugen will be Eligible to Receive $10 Million Milestone Payment upon Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer
-
Presage Biosciences Announces New Pharma Partnership to Evaluate Novel Immuno-Oncology Drug Combinations with CIVO® Technology
-
Compugen Reports Third Quarter 2023 Results
-
SOPHiA GENETICS Enters New Collaboration with Memorial Sloan Kettering Cancer Center and AstraZeneca to Address Global Inequalities in Comprehensive Cancer Care
-
Fusion Pharmaceuticals Announces Presentation of Preclinical Data Supporting FPI-2068, a Novel Targeted Alpha Therapy for EGFR-cMET Expressing Cancers
-
LaNova Medicines Announces Global Exclusive License Agreement with AstraZeneca for LM-305, a Novel GPRC5D-Targeting Antibody Drug Conjugate
-
Shanghai Cellular Biopharmaceutical Group presents first data from Phase I trial evaluating a novel CAR-T in advanced liver cancer at AACR Annual Meeting
-
New analysis of Phase II data at AACR assesses ImaginAb's investigational CD8 ImmunoPET technology's ability to predict response in immunotherapy
-
Fusion Pharmaceuticals Announces IND Clearance for FPI-2068, a Jointly Developed Novel Targeted Alpha Therapy
-
Keymed and Lepu Biopharma Jointly Announce Global Exclusive Licence Agreement with AstraZeneca for CMG901
-
Rilvegostomig, AstraZeneca's Bi-specific Antibody Derived from Compugen's COM902, Expected to Progress into Phase 3
-
Invitae Announces Partnership for Real-World Data Sharing to Inform Rare Cancer Research
-
HONEYWELL BEGINS PRODUCTION OF NEAR-ZERO GLOBAL-WARMING-POTENTIAL MEDICAL PROPELLANT
-
Baili Announces Clinical Trial Collaboration to Evaluate SI-B001, an EGFR x HER3 bispecific Antibody, in Combination with Tagrisso® in Patients with Non-Small Cell Lung Cancer
-
Blueprint Medicines Reports First Quarter 2022 Results
-
Blueprint Medicines Announces BLU-945 Proof-of-Concept Data Supporting Initiation of Comprehensive Combination Development Strategy in EGFR-mutant Non-Small Cell Lung Cancer
-
Harbour BioMed Announces Global Out-License Agreement with AstraZeneca for CLDN18.2xCD3 Bispecific Antibody HBM7022
-
PGA Champion Jason Day Launches Getting Out of the Rough Video Series With AstraZeneca to Support Lung Cancer Biomarker Testing Awareness
-
HONEYWELL TEAMS WITH ASTRAZENECA TO DEVELOP NEXT-GENERATION RESPIRATORY INHALERS THAT USE NEAR-ZERO GLOBAL WARMING POTENTIAL PROPELLANT
-
Glenmark inks agreement with AstraZeneca to commercialize its product Pulmicort Respules® in Colombia
-
Fusion Pharmaceuticals Announces Nomination of First Targeted Alpha Therapy Candidate in Collaboration with AstraZeneca to Advance into IND-Enabling Studies for Phase 1 Development
-
Integral Molecular Adds Transgenic Humanized Mice to Expand its MPS Antibody Discovery Platform Through a Partnership with Alloy Therapeutics
-
Samsung Biologics and AstraZeneca expand strategic manufacturing partnership to include COVID-19 and cancer therapy
-
Deutsche Bank's Depositary Receipts Virtual Investor Conference presentations now available for on-demand viewing
-
International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on November 16th and 17th, 2021
-
Integral Molecular Enters into Antibody License Agreement with AstraZeneca for Oncology Therapeutics
-
SAGA Diagnostics enters into an assay development agreement with AstraZeneca
-
Compugen Announces Milestone Payment from AstraZeneca Triggered by First Patient Dosed with TIGIT Bispecific Derived from COM902
-
Compugen Announces Bispecific Antibody Derived from COM902 to Enter Clinical Development
-
Aridis Pharmaceuticals Announces Exclusive License of Suvratoxumab, a Phase 3-Ready Monoclonal Antibody, from AstraZeneca
-
Moderna Set to Join S&P 500
-
Targovax announces completed enrollment in the phase 1/2 trial with ONCOS-102 in combination with durvalumab in patients with advanced colorectal cancer with peritoneal malignancies
-
PathAI to Present Machine Learning-based Quality Control Tool for HER2 Testing in Breast Cancer at the American Society of Clinical Oncology Virtual Scientific Program 2021
-
Amgen Announces Tezepelumab Biologics License Application Submitted To U.S. FDA
-
Geneseeq and AstraZeneca Collaborate to Build Guangzhou Bio-Diagnostics Innovation Center
-
AliveCor Announces Collaboration with AstraZeneca to Develop Non-Invasive Potassium Monitoring Solutions
-
Recombinetics Inc. Announces Neurofibromatosis Type 1 Research Collaboration with AstraZeneca
-
Compugen Announces First Development Milestone in License Agreement with AstraZeneca for the Development of Bispecific and Multi-specific Antibody Products
-
Fusion Pharmaceuticals Announces Collaboration with AstraZeneca to Develop and Commercialize Next-Generation Radiopharmaceuticals and Combination Therapies
-
Targovax announces that the ONCOS-102 and durvalumab trial successfully completes part 1 in colorectal cancer
-
Australian Therapeutic Goods Administration Approves the First Phase I Trial of ATG-017 for the Treatment of Patients with Advanced Solid Tumors and Hematological Malignancies
-
Ascentage Pharma Enters Clinical Collaboration to Evaluate the Combination of Bcl-2 and BTK Inhibitors
-
AbbVie and Allergan Announce Agreements to Divest Brazikumab and Zenpep
-
SK Holdings strengthens partnership with AstraZeneca, a global bio-pharmaceutical company
-
Antengene Corporation Announces Exclusive Worldwide License to Develop and Commercialize AZD0364
-
ImaginAb signs multi-party collaboration agreement with three global pharmaceutical companies to help further develop company's CD8 ImmunoPET technology
-
Theragnostics Signs Agreement with AstraZeneca
Back to AZN Stock Lookup
